// App-Quantinova.ai

: A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Researchers

Presenter

  • Sanfang Tu

Principal Investigators

  • Lan Deng

  • Rui Huang

  • Xuan Zhou

  • Jilong Yang

  • Weijun Zhou

  • Meifang Li

  • Chunyan Yue

  • Shaojie Wu

  • Zhenling Guo

  • Lung-Ji Chang

  • Yuhua Li

Medical Centers

  • Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

  • Geno-immune Medical Institute, Shenzhen, China

  • UESTC, School of Medicine, Chengdu, China

  • Molecular Genetics and Microbioloby, University of Florida, Gainesville, FL

Locations

  • China

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Cluster of Differentiation 19

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved